Sulpiride first appeared in published literature in 1967. Clinical studies show a greater effect on treating the negative symptoms of schizophrenia rather than positive symptoms at low doses, though the effects are more equal at higher doses.
Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.
Sulpiride is indicated for the treatment of acute and chronic schizophrenia.
Donders Centre for Cognition, Radboud University, Nijmegen, Gelderland, Netherlands
Department of Psychology, Differential Psychology and Personality Research, Philipps-University of Marburg, Marburg, Hessen, Germany
Shengliang Chen, Shanghai, China
Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
Bezirkskrankenhaus Augsburg, Augsburg, Germany
Krankenhaus Hedwigshöhe, Berlin, Germany
Hannover Medical School, Hannover, Germany
Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar, Munich, Bavaria, Germany
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
Pharmaceutics Department, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
Department of Clinical Pharmacology, Vienna, Austria
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.